AI assistant
Sending…
SMS Pharmaceuticals Ltd — Capital/Financing Update 2022
Oct 18, 2022
62302_rns_2022-10-18_8f3823b2-4f62-4a81-8e71-b99fcb4a6ff2.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [154 x 50] intentionally omitted <==
| To | |
|---|---|
| The Manager, | The Manager, |
| Corporate Filings Department, | Listing Compliance Department, |
| BSELimited, | National Stock ExchangeofIndia Ltd. |
| Phiroze Jeejeebhoy Towers, | ExchangePlaza,Plot no.C/l,G Block, |
| Dalal Street, | Bandra-Kurla Complex, Bandra(E), |
| Mumbai- 400 001. | Mumbai - 400 051. |
| Security Code: 532815 | Symbol: SMSPHARMA |
| S.No | Particulars | Details |
|---|---|---|
| 1 | nameofthe target entity, details inbrief suchassize,turnoveretc.; | M/ s. Provenio Astral InternationalLLP(Formerly KnownasStudiom SquareLLP)LLPIN:AAM-1951.TheCapitalContributionoftheLLPisRs.2,00,00,000/- and Revenueason 31stMarch,2022isNil. |
==> picture [81 x 86] intentionally omitted <==
| 2 | Whethertheacquisition would fall | No | ||||
| withinrelated party transaction(s) and | ||||||
| whetherthepromoter/promoter | ||||||
| group/group companies have any | ||||||
| interest intheentitybeing acquired? If | ||||||
| yes,natureofinterest and details | ||||||
| thereofandwhetherthesameisdone | ||||||
| at"arms length"; | ||||||
| 3 | industrytowhich | theentitybeing | Other Business activities | |||
| acquiredbelongs | ||||||
| 4 | objects and effectsofacquisition | M/s.Provenio Astral InternationalLLP | ||||
| (includingbut | notlimitedto, | (FormerlyKnownasStudiom | SquareLLP) | |||
| disclosureofreasonsforacquisitionof | is engaged in the business | ofBuying, | ||||
| target entity,ifits | businessisoutside | Selling, Importing,Exporting, | Promoting, | |||
| the mainlineofbusinessofthe listed | Marketing,Dealing in all typesofgoods | |||||
| entity); | on Wholesaleaswellason | Retail basis | ||||
| and other businessactivities. | ||||||
| Provenio Astral is proposed | todevelop | |||||
| pharmaceutical parksinvarious countries | ||||||
| especially in Southeast Asian Countries. | ||||||
| Thisstrategicpartnership may help t he | ||||||
| companytoexpand its business in | ||||||
| overseas and alsoIftheCompany wishto | ||||||
| establish any facility in overseas in future. | ||||||
| This partnership will benefit | toprocure | |||||
| esta blishedconnectivity facilitywith | ||||||
| lesser price than the market,fromthe | ||||||
| above said proposed projects. | ||||||
| 5 | briefdetailsofany governmentalor | Not Applicable | ||||
| regulatory approvals requiredforthe | ||||||
| acquisition; | ||||||
| 6 | indicativetimeperiodforcompletion | The companyhasacquired | 4.9%of | |||
| oftheacquisition; | capital contribution in M/s. Provenio | |||||
| AstralInternationalLLP, | hasbeen | |||||
| completed on 18thOctober, 2022. | ||||||
| 7 | natureofconsideration -whethercash | CashConsideration Payment through | ||||
| considerationor | share swap and | Bank Cheque. | ||||
| detailsofthesame | ||||||
Thirumale Digitally signed by Thirumalesh Tumma sh Tumma Date: 2022.10.18 18:03:59 +05'30'
More from SMS Pharmaceuticals Ltd
Call Transcript
2026
May 30
Report Publication Announcement
2026
May 27
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 25
Report Publication Announcement
2026
May 25
Investor Presentation
2026
May 23
Investor Presentation
2026
May 23
Earnings Release
2026
May 23
Earnings Release
2026
May 23
Regulatory Filings
2026
May 22